UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 10-Q

 


 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarter ended March 31, 2024

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                             to                          

 

Commission File Number 000-53601

 

 

MITESCO, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada

 

87-0496850

(State Other Jurisdiction of Incorporation or Organization)

 

(I.R.S. Employer Identification Number)

 

505 Beachland Blvd., Suite 1377

Vero Beach, Florida 32963

(Address of principal executive offices) (Zip code)

 

844-383-8689

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

 

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large, accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer

Smaller reporting company

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No

 

As of May 12, 2024, the registrant had outstanding 5,935,044 shares of common stock issued and outstanding.

 

 

 

 

Table of Contents

 

  Page

PART I  FINANCIAL INFORMATION

 

 

 

 

Item 1.

Financial Statements (Unaudited)

4

 

Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023

4

 

Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023

5

 

Consolidated Stockholder’s Deficit for the three months ended March 31, 2024 and 2023

6

 

Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023

7

 

Notes to Consolidated Financial Statements

8

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

27

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

29

 

 

 

Item 4.

Controls and Procedures.

29

 

 

 

PART II  OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings.

30

 

 

 

Item 1A.

Risk Factors.

32

 

 

 

Item 2.

Sale of Unregistered Securities.

32

 

 

 

Item 3.

Defaults Upon Senior Secured Securities.

32

 

 

 

Item 4.

Mine Safety Disclosures.

32

 

 

 

Item 5.

Other Information.

32

 

 

 

Item 6.

Exhibits.

32

 

 

 

Signatures

34

 

 

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

MITESCO, INC.

CONSOLIDATED BALANCE SHEETS

 

   

March 31, 2024

(Unaudited)

   

December 31, 2023

 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 40,785     $ 2,838  

Prepaids and other current assets

    15,000       -  

Total current assets

    55,785       2,838  
                 

Total assets

  $ 55,785     $ 2,838  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

               

Current liabilities:

               

Accounts payable and accrued liabilities

  $ 7,393,234     $ 7,838,112  

Accrued interest

    389,444       348,821  

Accrued interest - related party

    72,374       61,792  

Derivative liabilities

    152,945       152,945  

Lease liability - operating lease, current

    99,477       99,477  

Notes payable, net

    1,145,429       945,429  

Notes payable - related parties, net

    300,012       300,012  

SBA loan payable

    414,002       421,788  

Other current liabilities

    96,136       121,136  

Preferred stock dividends payable

    2,049,289       1,551,833  

Preferred stock dividends payable - related parties

    161,617       73,364  

Legal settlements

    2,452,768       2,219,886  

Total current liabilities

    14,726,727       14,134,595  
                 

Total liabilities

    14,726,727       14,134,595  
                 

Stockholders' equity (deficit)

               

Preferred stock, $0.01 par value, 100,000,000 shares authorized; 500,000 shares designated Series A; 3,000,000 shares designated Series C; 10,000,000 shares designated Series D; 10,000 shares designated as Series E; 140,000 shares designated as Series F, and 27,324 shares designated Series X.

               

Preferred stock, Series A, $0.01 par value, 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023

    -       -  

Preferred stock, Series C, $0.01 par value, 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023

    -       -  

Preferred stock, Series D, $0.01 par value, 250,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023

    2,500       2,500  

Preferred stock, Series F, $0.01 par value, 20,057 shares issued and outstanding as of March 31, 2024 and December 31, 2023

    201       201  

Preferred stock, Series X, $0.01 par value, 24,227 shares issued and outstanding at March 31, 2024 and December 31, 2023

    242       242  

Common stock, $0.01 par value, 500,000,000 shares authorized, 5,634,027 and 5,567,957 shares issued and outstanding as of March 31, 2024 and December 31, 2023 , respectively

    56,341       55,680  

Additional paid-in capital

    47,270,074       47,856,444  

Accumulated deficit

    (62,000,300 )     (62,046,824 )
                 

Total stockholders' equity (deficit)

    (14,670,942 )     (14,131,757 )
                 

Total liabilities and stockholders' equity (deficit)

  $ 55,785     $ 2,838  

 

See accompanying notes to these unaudited consolidated financial statements.

 

4

 

MITESCO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

Three Months Ended

 
   

March 31, 2024

   

March 31, 2023

 

OPERATING EXPENSES:

               
                 

General and administrative

  $ 135,476     $ 1,629,903  

Impairment of fixed assets

    -       128,465  
                 

Total operating expenses

    135,476       1,758,368  
                 

Net loss from operations

    (135,476 )     (1,758,368 )
                 

OTHER INCOME (EXPENSES):

               

Interest expense

    (46,130 )     (1,376,066 )

Interest expense - related parties

    (5,075 )     (43,569 )

Gain on termination of operating lease

    233,205       -  

(Loss) Gain on revaluation of derivative liabilities

    -       (110,778 )

Total other income (expense)

    182,000       (1,530,413 )
                 

Net income (loss) from continuing operations

    46,524       (3,288,781 )

Net loss from discontinued operations

    -       (2,325,044 )

Consolidated net income (loss)

    46,524       (5,613,825 )
                 

Preferred stock dividends

    (550,312 )     (61,823 )

Preferred stock dividends - related parties

    (88,253 )     (17,996 )
                 

Net loss available to common shareholders

  $ (592,041 )   $ (5,693,644 )
                 

Net loss per common share - continuing operations

  $ (0.11 )   $ (0.70 )

Net loss per common share - discontinued operations

  $ -     $ (0.48 )

Net loss per common share

  $ (0.11 )   $ (1.18 )
                 

Weighted average shares outstanding

    5,593,991     $ 4,825,054  

 

See accompanying notes to these unaudited consolidated financial statements.

 

5

 

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSEQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED MARCH 31, 2024 and 2023

(UNAUDITED)

 

   

Preferred Stock

Series C

 

Preferred Stock

Series D

 

Preferred Stock

Series F

 

Preferred Stock

Series X

 

Common Stock

 

Additional

Paid-in

 

Common

Stock

 

Accumulated

       
   

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Subscribed

 

Deficit

 

Total

 
                                                                                       

Balance, December 31, 2023

    -   $ -     250,000   $ 2,500     20,057   $ 201     24,227   $ 242     5,567,957   $ 55,680   $ 47,856,444   $ -   $ (62,046,824 ) $ (14,131,757 )
                                                                                       

Shares issued for Series X dividends

    -     -     -     -     -     -     -     -     66,070     661     52,195     -     -     52,856  

Preferred stock dividends

    -     -     -     -     -     -     -     -     -     -     (638,565 )   -     -     (638,565 )

Net income

    -     -     -     -     -     -     -     -     -     -     -     -     46,524     46,524  
                                                                                       

Balance, March 31, 2024

    -   $ -     250,000   $ 2,500     20,057   $ 201     24,227   $ 242     5,634,027   $ 56,341   $ 47,270,074   $ -   $ (62,000,300 ) $ (14,670,942 )
                                                                                       

Balance, December 31, 2022

    1,047,619     10,476     3,100,000     31,000     -     -     24,227     242     4,630,372     46,305     29,452,514     36,575     (48,714,461 )   (19,137,349 )
                                                                                       

Shares issued for conversion of note payable

    -     -     -     -     -     -     -     -     57,138     571     82,885     -     -     83,456  

Vesting of stock options issued to employees

    -     -     -     -     -     -     -     -     -     -     933     -     -     933  

Shares issued to service providers

    -     -     -     -     -     -     -     -     300,000     3,000     894,000     -     -     897,000  

Shares issued for Series X dividends

    -     -     -     -     -     -     -     -     8,063     81     35,248     -     -     35,329  

Preferred stock dividends

    -     -     -     -     -     -     -     -                 (79,818 )   -     -     (79,818 )

Net loss

    -     -     -     -     -     -     -     -     -     -     -     -     (5,613,825 )   (5,613,825 )
                                                                                       

Balance, March 31, 2023

    1,047,619   $ 10,476     3,100,000   $ 31,000     -   $ -     24,227   $ 242     4,995,573   $ 49,957   $ 30,385,762   $ 36,575   $ (54,328,286 ) $ (23,814,274 )

 

See accompanying notes to these unaudited consolidated financial statements.

 

6

 

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   

Three Months Ended

 
   

March 31, 2024

   

March 31, 2023

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               

Net income (loss)

  $ 46,524     $ (3,288,781 )

Adjustments to reconcile net income(loss) to net cash provided by (used in) operating activities:

               

Impairment of right of use asset

    -       83,810  

Depreciation expense

    -       11,393  

Penalties on notes payable

    -       1,102,778  

Amortization of discount on notes payable

    -       23,538  

Amortization of discount on notes payable - related parties

    -       11,131  

Share based compensation

    -       897,933  

Gain (loss) on lease terminations

    (233,205 )     -  

Gain (loss) on revaluation of derivative liabilities

    -       110,778  

Changes in operating assets and liabilities:

               

Prepaid expenses

    (15,000 )     (8,198 )

Accounts payable and accrued liabilities

    21,209       501,998  

Other current liabilities

    (25,000 )     25,000  

Accrued interest

    40,623       163,770  

Accrued interest - related parties

    10,582       26,724  

Net cash used in operating activities from continuing operations

    (154,267 )     (338,126 )

Net cash provided by operating activities from discontinued operations

    -       302,802  

Net cash provided by (used in) operating activities

    (154,267 )     (35,324 )
                 
                 

CASH FLOWS FROM FINANCING ACTIVITIES:

               

Principal payments on SBA Loan

    (7,786 )     -  

Proceeds from notes payable, net of discounts

    200,000       -  

Net cash provided by financing activities from continuing operations

    192,214       -  

Net cash provided by financing activities from discontinued operations

    -       -  

Net cash provided by financing activities

    192,214       -  
                 

Net change in cash

    37,947       (35,324 )

Cash at beginning of period

    2,838       35,623  

Cash at end of period

  $ 40,785     $ 299  
                 

Supplemental disclosure of cash flow information:

               

Cash paid for interest

  $ -     $ -  

Cash paid for taxes

  $ -     $ -  
                 

Supplemental disclosure of financing cash flow information:

               

Stock Issued for common stock subscribed

  $ -     $ 83,456  

Preferred stock dividends

  $ 638,565     $ 79,818  

Discount on notes payable due to warrants

  $ -     $ 94,672  

Increase in capital expenditures included in accounts payable

  $ -     $ 109,383  

Shares issued for Series X dividends

  $ 52,856     $ -  

 

See accompanying notes to these unaudited consolidated financial statements.

 

7

 

MITESCO, INC.

UNAUDITED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1: Description of Business

 

Company Overview

 

Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company completed a move of its corporate status to Nevada from Delaware in order to effect reduced costs.

 

The details can be found at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518523001074/mitesco20231016_8k.htm .

 

From 2020 through 2022, our operations were focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and had six operating clinics during the year ended December 31, 2022, with two additional sites under contract. In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability.

 

We are a holding company seeking to provide products, services and technology. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates. During the first quarter of 2024 we recruited a number of individuals to a newly formed Advisory Board, who might assist the Company in determining the viability of certain ventures going forward. These individuals have a background in data center services, cyber and data security and software applications related to infrastructure design, implementation and management including geographical information systems (GIS). We expect to announce in the second quarter of 2024 the formation of a new, wholly owned subsidiary whose business will be focused on those areas generally.

 

Note 2: Going Concern

 

As of March 31, 2024, the Company had cash and cash equivalents of approximately $41,000, current liabilities of approximately $14.7 million, and has incurred significant losses from the previous clinic operations. As previously noted, we made a strategic decision to reduce our capital needs by closing our entire clinic operations in the fourth quarter of 2022 and releasing our entire staff, due to lack of profitability. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

 

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists.

 

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

 

Note 3: Summary of Significant Accounting Policies

 

Basis of Presentation – The consolidated financial statements are prepared in conformity with accounting principles accepted in the United States of America (“GAAP”).

 

The consolidated financial statements and related disclosures as of March 31, 2024 are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. In our opinion, these unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary for the fair statement of the results for the interim periods. These unaudited financial statements should be read in conjunction with the audited financial statements of the Company for the years ended December 31, 2023 and 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 16, 2024. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year ended December 31, 2024.

 

8

 

Principles of Consolidation The accompanying consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC and The Good Clinic, LLC. In addition, we relied on the operating activities of certain legal entities in which we did not maintain a controlling ownership interest, but over which we had indirect influence and of which we were considered the primary beneficiary. These entities are typically subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restriction and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

 

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options, and convertible instruments. For the three months ended March 31, 2024 and 2023, all potentially dilutive instruments were excluded from the calculation of net loss per share as their effect was antidilutive.

 

Discontinued Operations - The accompanying financial statements are prepared with the guidance of ASU 2014-08, “Reporting Discontinued Operations”, and ASC Topic 205, Presentation of Financial Statements, and ASC Topic 360, Property, Plant and Equipment.

 

Recent Accounting Standards – In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.

 

There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

 

Note 4: Discontinued Operations

 

In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability. On December 8, 2023, the Company sold the remaining assets of The Good Clinic, LLC to Leading Primary Care LLC, a company organized by Michael C. Howe, the former CEO of The Good Clinic, LLC for total consideration of approximately $2.5 million. ASC 360-10-45-9 requires that a long-lived asset (disposal group) to be sold shall be classified as held for sale in the period in which a set of criteria have been met, including criteria that the sale of the asset (disposal group) is probable and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. This criteria was achieved on December 8, 2023. Additionally, the discontinued operations are comprised of the entirety of The Good Clinic, LLC. For comparability purposes certain prior period line items relating to the assets held for sale have been reclassified and presented as discontinued operations for all periods presented in the accompanying consolidated statements of net loss and comprehensive loss and the consolidated balance sheets.

 

9

 

The Company had no assets or liabilities classified that were classified as held as part of discontinued operations as of March 31, 2024 or December 31, 2023.

 

The following information presents the major classes of line items constituting the after-tax loss from discontinued operations in the consolidated statements of operations:

 

   

Three Months Ended

 
   

March 31,

   

March 31,

 
   

2024

   

2023

 

Revenue

  $ -     $ -  

Cost of goods sold

    -       2,419  

Gross margin

    -       (2,419 )
                 

Selling, general, and administrative expenses

    -       (381,501 )

Impairment of assets

    -       (2,143,428 )
                 

Other (income) expense:

               

Gain on termination of operating lease

    -       287,897  

Interest expense

    -       (85,593 )

Loss from discontinued operations, net of tax

  $ -     $ (2,325,044 )

 

The following information presents the major classes of line items constituting significant operating and investing cash flow activities in the consolidated statements of cash flows relating to discontinued operations:

 

   

Three Months Ended

 
   

March 31,

   

March 31,

 
   

2024

   

2023

 
                 

Depreciation expense

  $ -     $ 33,262  

Impairment of property and equipment

  $ -     $ 2,271,893  

Changes in accounts payable and accrued liabilities

  $ -     $ 549,929  

 

Note 5: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at March 31, 2024 and December 31, 2023:

 

   

March 31,

   

December 31,

 
   

2024

   

2023

 

Trade accounts payable

  $ 6,604,738     $ 7,094,334  

Accrued payroll and payroll taxes

    788,496       743,778  

Total accounts payable and accrued liabilities

  $ 7,393,234     $ 7,838,112  

 

Note 6: Right to Use Assets and Lease Liabilities Operating Leases

 

The Company had operating leases for its clinics for which the Company is currently in negotiations with the Lessors to settle the remaining amounts owed after closing the clinic facilities. The Company’s lease expense was entirely comprised of operating leases and is reported as a component of discontinued operations as a result of closing of the clinics and the subsequent sale of the assets. As of December 31, 2023, the Company had impaired all balances of the related right to use assets.

 

Operating lease liabilities are summarized below:

 

   

March 31,

2024

   

December 31,

2023

 

Lease liability

  $ 99,477     $ 99,477  

Less: current portion

    (99,477 )     (99,477 )

Lease liability, non-current

  $ -     $ -  

 

As a result of closing the facilities, the Company has made no further lease payments during the year ending December 31, 2023 or the three months ended March 31, 2024. As of March 31, 2024 the Company has either settled amounts owed or entered in into default judgements for all leases except for the office lease. For all leases for which a legal settlement have been entered into, all amounts have been reclassified to legal settlements as of March 31, 2024 and December 31, 2023.

 

10

 

For the period ended December 31, 2024

  $ 99,477  

For the period ended December 31, 2025

    -  

For the period ended December 31, 2026

    -  

For the period ended December 31, 2027

    -  

For the period ended December 31, 2028

    -  

Thereafter

    -  

Total

  $ 99,477  

Less: Present value discount

    -  

Lease liability

  $ 99,477  

 

As of December 31, 2023, the Company has entered into settlement agreements for certain of our leases in the amount of $2,219,886 which is recorded as Legal Settlements in the accompanying balance sheet. During the three months ended March 31, 2024, the Company recorded a gain of $233,205 as a result of a final settlement in addition to reclassifying certain accounts payable related to the leases to legal settlements. As of March 31, 2024 the Company has total legal settlement agreements in the amount of $2,452,768 which is recorded as Legal Settlements in the accompanying balance sheet.

 

Note 7: SBA Loan Payable

 

PPP Loan Conversion to SBA Loan

 

During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration (the “SBA”). On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year.

 

On July 12, 2023, the Company received confirmation of a payment plan arrangement from the SBA. Pursuant to this payment plan, the Company agreed to pay a minimum of $2,595 each month until the loan is paid in full in July 2028. The SBA confirmed the balance due on the loan, including principal and interest, was $467,117. The Company will amortize the balance due on the loan including interest at the original PPP loan rate of 1% per annum; a gain on restructure of debt in the amount of $40,622 was recorded on this transaction during the year ended December 31, 2023, and the balance of the loan was recorded at the amount of $433,343 representing the net cash flows discounted at 1%. During the three months ended March 31, 2024, the Company made principal payments of $7,786 on this loan and recorded interest in the amount of $1,052.

 

Note 8: Notes Payable

 

The following table summarizes the outstanding notes payable as of March 31, 2024 and December 31, 2023, respectively:

 

   

March 31, 2024

   

December 31, 2023

 

Kishon Note

  $ 431,666     $ 431,666  

Finnegan Note 1

    51,765       51,765  

Finnegan Note 2

    32,353       32,353  

Schrier Note

    25,882       25,882  

Nommsen Note

    64,705       64,705  

Caplan Note

    64,705       64,705  

Finnegan Note 3

    32,353       32,353  

Lightmas Note

    66,000       66,000  

Lewis Note

    33,000       33,000  

Goff Note

    33,000       33,000  

Hagan Note

    110,000       110,000  

Cavalry Note 1

    25,000       -  

Cavalry Note 2

    50,000       -  

Mercer Note 1

    25,000       -  

Mercer Note 2

    50,000       -  

ABJ Note

    50,000       -  

Notes Payable

  $ 1,142,429     $ 945,429  
                 

Current Portion

  $ 1,145,429     $ 945,429  

Long-term portion

  $ -     $ -  

 

11

 

Kishon Note

 

On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793.

 

The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492.

 

During the year ended December 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note. At December 31, 2023, principal and interest in the amount of $431,666 and $88,909, respectively, were due on the Kishon Note. At March 31, 2024, principal and interest in the amount of $431,666 and $108,281, respectively, were due on the Kishon Note. This note was in default at March 31, 2024.

 

Finnegan Note 1

 

On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1.

 

Principal and accrued interest in the amount of $51,765 and $11,889, respectively, were due on this note at December 31, 2023. At March 31, 2024, principal and interest in the amount of $51,765 and $14,030, respectively, were due on the Kishon Note. This note was in default at March 31, 2024.

 

Finnegan Note 2

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2.

 

12

 

At December 31, 2023principal and accrued interest in the amount of $32,353 and $7,341, respectively, were due on this note. At March 31, 2024, principal and interest in the amount of $32,353 and $8,679, respectively, were due on the Kishon Note. This note was in default at March 31, 2024.

 

Schrier Note

 

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note.

 

At December 31, 2023, principal and accrued interest in the amount of $25,882 and $5,383, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $25,882 and $6,454, respectively, were due on this note. This note was in default at March 31, 2024.

 

Nommsen Note

 

On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $13,685, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $64,705 and $16,361, respectively, were due on this note. This note was in default at March 31, 2024.

 

Caplan Note

 

On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note.

 

13

 

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $12,989, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $64,705 and $15,665, respectively, were due on this note This note was in default at March 31, 2024.

 

Finnegan Note 3

 

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3.

 

At December 31, 2023, principal and accrued interest in the amount of $32,353 and $6,350, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $32,353 and $7,688, respectively, were due on this note. This note was in default at March 31, 2024.

 

Lightmas Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $60,000 to Frank Lightmas (the “Lightmas Note”). The Lightmas Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lightmas Note was $51,000; the amount payable at maturity will be $60,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lightmas Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lightmas Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lightmas Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Lightmas reasonably believes contains a term that is more favorable than those in the Lightmas Note, the Company shall notify Mr. Lightmas of such term, and such term, at the option of Mr. Lightmas, shall become a part of the Lightmas Note. In addition, Mr. Lightmas received 492 shares of common stock with a value of $2,640; this amount was recorded as a discount to the Lightmas Note.

 

At December 31, 2023, principal and accrued interest in the amount of $66,000 and $13,325, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $66,000 and $16,055, respectively, were due on this note. This note was in default at March 31, 2024.

 

Lewis Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Lisa Lewis (the “Lewis Note”). The Lewis Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lewis Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lewis Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lewis Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lewis Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lewis reasonably believes contains a term that is more favorable than those in the Lewis Note, the Company shall notify Ms. Lewis of such term, and such term, at the option of Ms. Lewis, shall become a part of the Lewis Note. In addition, Ms. Lewis received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Lewis Note.

 

14

 

At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $33,000 and $8,028, respectively, were due on this note. This note was in default at March 31, 2024.

 

Goff Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Sharon Goff (the “Goff Note”). The Goff Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Goff Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Goff Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Goff Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Goff Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Goff reasonably believes contains a term that is more favorable than those in the Goff Note, the Company shall notify Ms. Goff of such term, and such term, at the option of Ms. Goff, shall become a part of the Goff Note. In addition, Ms. Goff received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Goff Note.

 

At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $33,000 and $8,028, respectively, were due on this note. This note was in default at March 31, 2024.

 

Hagan Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Cliff Hagan (the “Hagan Note”). The Hagan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Hagan Note was $85,000; the amount payable at maturity will be $100,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Hagan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Hagan Note entered default status on December 11, 2022, and the interest rate increased to 18%. The Hagan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Hagan reasonably believes contains a term that is more favorable than those in the Hagan Note, the Company shall notify Mr. Hagan of such term, and such term, at the option of Mr. Hagan, shall become a part of the Hagan Note. In addition, Mr. Hagan received 820 shares of common stock with a value of $4,715; this amount was recorded as a discount to the Hagan Note.

 

At December 31, 2023, principal and accrued interest in the amount of $110,000 and $21,793, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $110,000 and $26,343, respectively, were due on this note. This note was in default at March 31, 2024.

 

Cavalry 2024 Note 1

 

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Cavalry Fund LLP (“Cavalry”), (the “Cavalry Note 1”) with a due date of January 23, 2025. The Cavalry Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At March 31, 2024, principal and accrued interest in the amount of $25,000 and $465, respectively, were due on this note.

 

Cavalry 2024 Note 2

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to the Cavalry, (the “Cavalry Note 2”) with a due date of February 28, 2025. The Cavalry Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At March 31, 2024, principal and accrued interest in the amount of $50,000 and $431, respectively, were due on this note.

 

15

 

Mercer 2024 Note 1

 

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Mercer Street Global Opportunity Fund (“Mercer”), (the “Mercer Note 1”) with a due date of January 23, 2025. The Mercer Note bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At March 31, 2024, principal and accrued interest in the amount of $25,000 and $465, respectively, were due on this note.

 

Mercer 2024 Note 2

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mercer, (the “Mercer Note 2”) with a due date of February 28, 2025. The Mercer Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At March 31, 2024, principal and accrued interest in the amount of $50,000 and $431, respectively, were due on this note.

 

AJB 2024 Note

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to the AJB Capital Investments, LLC (“AJB”), (the “AJB Note”) with a due date of February 28, 2025. The AJB Note bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At March 31, 2024, principal and accrued interest in the amount of $50,000 and $431, respectively, were due on this note.

 

Aggregate interest expense on the above notes payable was $40,624 for the three months ended March 31, 2024. Accrued interest on notes payable was $389,444 and $348,821 at March 31, 2024 and December 31, 2023, respectively.

 

Note 9: Notes Payable Related Parties

 

The following table summarizes the outstanding related party notes payable as of March 31, 2024 and December 31, 2023, respectively

 

   

March 31,

2024

   

December 31,

2023

 

M Diamond Note

    64,706       64,706  

Dobbertin Note

    19,412       19,412  

Lindstrom Note

    45,294       45,294  

Mitchell Note

    78,100       78,100  

Leath Note

    55,000       55,000  

November 29, 2022 Notes

    37,500       37,500  

Notes Payable

    300,012       300,012  
                 

Current Portion, net of discount

  $ 300,012     $ 300,012  

Long-term portion, net of discount

  $ -     $ -  

 

16

 

M Diamond Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). Ms. Diamond is the daughter of Larry Diamond, former CEO. The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,706 and $14,682, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $64,706 and $16,169, respectively, were due on this note. This note was in default at March 31, 2024.

 

Dobbertin Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, who was the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note.

 

At December 31, 2023 principal and accrued interest in the amount of $19,412 and $4,405, respectively, were due on this note. At March 31, 2024 principal and accrued interest in the amount of $19,412 and $5,197, respectively, were due on this note. This note was in default at March 31, 2024.

 

Lindstrom Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, who was the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1.

 

17

 

At December 31, 2023, principal and accrued interest in the amount of $45,294 and $10,277, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $45,294 and $12,125, respectively, were due on this note. This note was in default at March 31, 2024.

 

Mitchell Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Mitchell Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Mitchell reasonably believes contains a term that is more favorable than those in the Mitchell Note, the Company shall notify Mr. Mitchell of such term, and such term, at the option of Mr. Mitchell, shall become a part of the Mitchell Note. In addition, Mr. Mitchell received 582 shares of common stock with a value of $3,124; this amount was recorded as a discount to the Mitchell Note.

 

At December 31, 2023, principal and accrued interest in the amount of $78,100 and $15,768, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $78,100 and $18,999, respectively, were due on this note. This note was in default at March 31, 2024.

 

Leath Note

 

On September 15, 2022, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mack Leath (the “Leath Note”). The Leath Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Leath Note was $42,500; the amount payable at maturity will be $50,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Leath Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Leath Note entered default status on December 16, 2022, and the interest rate increased to 18%. The Leath Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Leath reasonably believes contains a term that is more favorable than those in the Leath Note, the Company shall notify Mr. Leath of such term, and such term, at the option of Mr. Leath, shall become a part of the Leath Note. In addition, Mr. Leath received 410 shares of common stock with a value of $2,868; this amount was recorded as a discount to the Leath Note.

 

At December 31, 2023, principal and accrued interest in the amount of $55,000 and $10,757, respectively, were due on this note. At March 31, 2024, principal and accrued interest in the amount of $55,000 and $13,032, respectively, were due on this note. This note was in default at March 31, 2024.

 

November 29, 2022 Notes

 

On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, who was the Company’s CFO and Board Member; (2) Lawrence Diamond, who was the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, who was a Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, who was a Board Member; (6) Jenny Lindstrom, who was the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, who was the Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”).

 

18

 

The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 13. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022.

 

Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022.

 

During the year ended December 31, 2023, interest in the amount of $11,967 was accrued on the November 29 Notes.

 

On September 29, 2023, three of the November 29 Lenders (1) Thomas Brodmerkel, (2) Lawrence Diamond, and (3) Faraz Naqvi converted their November 29 Notes into shares of the Company’s Series F Preferred Stock as follows: Each of the noteholders converted an equity investment incentive in the amount of $13,553 representing 65% of the total amount due under the November 29 Note , along with original principal of $18,750 and accrued interest of $2,101 (a total of $34,404) into 34 shares of the Company’s Series F Preferred Stock. Other than the equity investment incentives of $13,553, there was no gain or loss recognized on this transaction as the Series F Preferred Stock was issued at its face value of $1,000 per share.

 

On September 29, 2023, one of the November 29 Lenders, Sheila Schweitzer, converted her November 29 Note into shares of the Company’s restricted common stock as follows: principal of $18,750 and accrued interest of $2,101 were converted at a price of $0.80 per share into 26,064 shares of the Company’s common stock.

 

On December 8, 2023 pursuant to the Howe debt exchange agreement, Mr. Howe exchanged his note in the principal amount of $18,750 and accrued interest of $2,682 for certain assets of the company. No amounts were due under the Howe note as of December 31, 2023.

 

At December 31, 2023, there was principal and interest in the aggregate amount of $37,500 and $5,903, respectively, due on the two November 29 Notes that are still outstanding. At March 31, 2024, there was principal and interest in the aggregate amount of $37,500 and $6,851, respectively, due on the two November 29 Notes that are still outstanding.

 

Aggregate interest expense as described on the above notes payable – related parties was $10,581 for the three months ended March 31, 2024. Accrued interest on notes payable – related parties was $72,374 and $61,792 at March 31, 2024 and December 31, 2023, respectively.

 

Note 10: Derivative Liabilities

 

Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Monte Carlo Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructure, and at each period end.

 

19

 

Derivative liability activity for the three months ended March 31, 2024 is summarized in the table below:

 

December 31, 2023

  $ 152,945  

True-up features issued

    -  

Settled upon conversion or exercise

    -  

Loss on revaluation

    -  

March 31, 2024

  $ 152,945  

 

The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following tables summarize the assumptions for the valuations:

 

   

March 31,

   

December 31,

 
   

2024

   

2023

 

Volatility

    475.7 %     95.1% to 123.2 %

Stock Price

  $ 0.0250     $ 1.06 to 3.50  

Risk-free interest rates

    5.21 %     4.35% to 4.37 %

Term (years)

    0.39       0.73 to 0.86  

 

Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation:

 

 

The stock price would fluctuate with the Company projected volatility.

 

The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation.

 

The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1.

 

In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions.

 

Discount rates were based on risk free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

 

Note 11: Stockholders Equity (Deficit)

 

Common Stock

 

The Company has authorized 500,000,000 shares of common stock, par value $0.01; 5,634,027 were issued and outstanding at March 31, 2024.

 

During the three months ended March 31, 2024, the Company issued 66,070 shares of common stock for dividends payable on its Series X Preferred Stock.

 

Preferred Stock

 

We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, 140,000 shares of Series F Preferred, and 24,227 shares as Series X Preferred Stock.

 

Series A Preferred Stock

 

The Series A Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share and accrued dividends at the rate of 12% on $25.00 per share. The Company had no shares of Series A Preferred Stock outstanding at March 31, 2024.

 

20

 

Series C Preferred Stock

 

The Series C Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series C ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder. The Company had no shares of Series C Preferred Stock outstanding at March 31, 2024.

 

Series D Preferred Stock

 

The Series D Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series D ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder. The Company had 250,000 shares of Series D Preferred Stock outstanding at March 31, 2024.

 

The Company accrued dividends in the amount of $3,928 on the Series D Preferred Stock for the three months ended March 31, 2024. As of March 31, 2024, the Company had $37,727 in accrued dividends on the Series D Preferred Stock.

 

Series E Preferred Stock

 

On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01. There are 0 shares of Series E Preferred Stock outstanding at March 31, 2024. No shares of Series E Preferred Stock have ever been issued.

 

As long as any shares of Series E are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series E, (a) alter or change the preferences, rights, privileges or powers given to the Series E or alter or amend the Certificate of Incorporation or bylaws, (b) increase or decrease (other than by conversion) the number of authorized shares of Series E, or (c) create or authorize any new class of shares that has a preference over Series E.

 

Unless previously converted into shares of Common Stock, any shares of Series E issued and outstanding, shall be redeemable at the option of the Company for cash at a redemption price per share equal to 110% of the initial issuance price, or $1,100, plus all dividends declared thereon.

 

Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05.

 

Series F Preferred Stock

 

On March 23, 2023, the Company filed a Certificate of Designations, Preferences and Rights of Series F 12% PIK $0.01 par value Convertible Perpetual Preferred Stock with the Delaware Secretary of State. The number of shares of Series F Preferred Stock designated is 140,000 and each share of Series F Preferred Stock has a liquidation preference of $1,000. The Series F Preferred Stock will rank senior to the Corporation’s Common Stock and on parity with all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank on parity with the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Corporation; and (iii) junior to all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank senior to the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Company.

 

Holders of shares of the Series F Preferred Stock are entitled to receive payment-in-kind dividends payable only in additional shares of Series F Preferred Stock (“PIK Dividends”) at rate of 12% per annum.

 

21

 

The Series F Preferred Stock will be convertible into common stock of the Company upon the listing of the Company’s stock on any of the following trading markets: the NYSE, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq Global Select Market. The conversion price will be calculated as 65% of the volume-weighted average price of the Company’s common stock on the conversion date. The number of shares issuable upon conversion will be calculated as the liquidation preference of the Series F Preferred stock plus any accrued but unpaid dividends divided by the conversion price.

 

There are 20,057 shares of Series F Preferred Stock outstanding at March 31, 2024

 

The Company accrued dividends in the amount of $608,393 on the Series F Preferred Stock for the three months ended March 31, 2024. As of March 31, 2024, the Company had $2,164,466 in accrued dividends on the Series F Preferred Stock.

 

Series X Preferred Stock

 

The Company has 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of December 31, 2023 and 2022. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Beginning in July 2023 the Company elected to use a price per share of $.80, a 20% discount to the average price of its common stock of $1.00, before the trading of its common stock was moved to the OTC Expert Market system. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.

 

On February 9, 2024, the Company issued 41,057 shares of common stock for dividends payable on its Series X Preferred Stock for the period from July 2023 through December 31, 2023.

 

On March 20, 2024, the Company issued a total of 25,013 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the first quarter of 2024 using the $.80 price per share as noted above.

 

The Company accrued dividends in the amount of $26,244 on the Series X Preferred Stock for the three months ended March 31, 2024. As of March 31, 2024, the Company had $0 in accrued dividends on the Series X Preferred Stock.

 

Stock Options

 

On January 21, 2021 the Company filed a Form S-8 containing the Mitesco Omnibus Securities and Incentive Plan (“the Plan”) with the SEC. In Sections 4.2 and 4.3 of the Plan it is noted that the Board of Directors has the authority for administration of the Plan. On January 7, 2024 the Board of Directors voted to a) cancel, revoke and terminate any previously issued options that have not already been exercised. For a number of technical reasons the Plan is no longer valid, and in addition to cancellation of any outstanding options, the Board has voted to formally terminate the Plan.

 

A copy of the Form S-8 which references the Plan can be found at: https://www.sec.gov/Archives/edgar/data/802257/000118518521000098/ex_221520.htm

 

The following table summarizes the options outstanding at March 31, 2024 and the related prices for the options to purchase shares of the Company’s common stock:

 

                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

options

   

contractual

   

outstanding

   

options

   

exercisable

 

prices

   

outstanding

   

life (years)

   

options

   

exercisable

   

options

 
$ 1.50       13,667       6.04     $ 1.50       13,667     $ 1.50  
          13,667       6.04     $ 1.50       13,667     $ 1.50  

 

22

 

The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 

Outstanding at December 31, 2023

    100,934     $ 10.01  

Granted

    -       -  

Cancelled/Expired

    (87,267 )   $ 11.38  

Exercised

    -       -  

Outstanding at March 31, 2024

    13,667     $ 1.50  

Options vested and exercisable

    13,667     $ 1.50  

 

At March 31, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $263,422 which vest upon various contingent requirements. At March 31, 2024, there was no intrinsic value on the issued or vested options.

 

Warrants

 

The following table summarizes the warrants outstanding on March 31, 2024, and the related prices for the warrants to purchase shares of the Company’s common stock:

 

                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

warrants

   

contractual

   

outstanding

   

warrants

   

exercisable

 

prices

   

outstanding

   

life (years)

   

warrants

   

exercisable

   

warrants

 
$ 2.50-37.50       673,208       2.42     $ 30.64       673,208     $ 30.64  
          673,208       2.42     $ 30.64       673,208     $ 30.64  

 

 

The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 
                 

Outstanding at December 31, 2023

    673,208     $ 30.64  

Granted

    -     $ -  

Exercised

    -     $ -  
Outstanding at March 31, 2024     673,208     $ 30.64  

 

At March 31, 2024, there was no intrinsic value on the issued or vested options.

 

Note 12: Fair Value of Financial Instruments

 

The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at March 31, 2024 and December 31, 2023 .

 

   

March 31, 2024

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  

 

   

December 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  

 

23

 

Note 13: Commitments and Contingencies

 

Legal

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. Mitesco (Company) was not named in the suit. We have settled this matter as of January 11, 2024 for total consideration consisting of a cash payment of $3,000.

 

On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

 

Nordhaus Clinic

 

On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received by the landlord and the Company believes no additional amounts are owed.

 

Egan Clinic a.k.a. Vikings

 

On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023 and the Company has released the property back to the leaseholder.

 

St. Paul Clinic a.k.a. The Grove

 

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023 in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

 

St. Louis Park Clinic a.k.a. Excelsior & Grand

 

On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,351 on April 2, 2024 and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024.

 

Eden Prairie Clinic a.k.a. TP Elevate

 

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations the amounts owed and is in the process of settling the remaining amounts owed.

 

24

 

Maple Grove Clinic a.k.a. Arbor Lakes

 

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company has released the property back to the leaseholder.

 

Radiant Clinic a.k.a. LMC Welton

 

On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder.

 

Quincy Clinic a.k.a. 1776 Curtis

 

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder.

 

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

 

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,768

 

 

 

Administrative offices

 

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not entered into a settlement agreement on this site as of the date of this filing but expect to shortly.

 

Note 14: Subsequent Events

 

Effective April 1, 2024 the Company intends to return to the dividend payment terms as defined in the Certificate of Designation for the Series X Preferred stock, as such the share price used in future dividend payment shall be determined using the closing price of the common stock on the 15th day of each month, and the shares shall be issued quarterly to reduce administrative costs.

 

25

 

Advisory Board

 

The Board of Directors recently authorized the creation of a new Advisory Board whose participants shall include subject matter experts in certain business areas under consideration by the Company. These positions are “non-executive” and as such are not governed by Section 16 of the Securities Act. The compensation for the participants shall be $60,000 per year paid through the issuance of restricted common stock. The per share valuation to be used shall be determined by the Board of Directors based on the market of the Company’s common stock at the time of the appointment.

 

On March 19, 2024, the Company announced its first participants to that Board. Each will receive $60,000 of restricted common stock for their services over the next 12 months. The Board has determined that the price per share for the restricted stock shall be $.80, the same pricing used for the payment of dividends to Series X Preferred shareholders. This results in the issuance of 75,000 shares for each member, in aggregate 225,000 shares of restricted common stock. On April 26, 2024 the Board authorized that the per share valuation to be used shall be determined by the Board of Directors based on the market of the Company’s common stock at the time of the appointment. The Board of Director has made April 1, 2024, the effective date for the Advisors appointed through April 1, 2024.

 

On April 26, 2024, the Company announced two additional participants to that Board. Each will receive $60,000 of restricted common stock for their services over the next 12 months. The Board has determined that the price per share for the restricted stock shall be $0.80, resulting in the issuance of 75,000 shares for each member, in aggregate 150,000 shares.

 

On May 10, 2024 the Company issued each of the above four (4) Advisors 75,000 shares of restricted common stock in consideration of their participation on the Advisory Board. The total of 300,000 restricted shares in aggregate were valued at $0.80 each as noted above.

 

 

26

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

References to the Company, Mitesco, Inc., our, us or we refer to Mitesco, Inc. The following discussion and analysis of the Companys financial condition and results of operations should be read in conjunction with the unaudited interim financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, could, would, expect, plan, anticipate, believe, estimate, continue, or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

 

History and Outlook

 

We are a holding company seeking to provide products, services and technology. From 2020 through 2022, the Company was executing against a strategic plan to open primary care clinics utilizing advanced degreed nurse practitioners in select markets. The clinics operated under the name The Good Clinic. However, the business failed to achieve profitability, and the markets were not favorable to additional funding, therefore in late 2022 the decision was made to close the clinics and release all employees.

 

We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates. During the first quarter of 2024 we recruited a number of individuals to a newly formed Advisory Board, who might assist the Company in determining the viability of certain ventures going forward. These individuals have a background in data center services, cyber and data security and software applications related to infrastructure design, implementation and management including geographical information systems (GIS). We expect to announce in the second quarter of 2024 the formation of a new, wholly owned subsidiary whose business will be focused on those areas generally. Until those announcements are made effective in the second quarter of 2024, the Company has no operating business other than the winding down of its previous operations.

 

Results of Operations

 

The following period-to-period comparisons of our financial results are not necessarily indicative of results for the current period of any future periods. Results of discontinued operations are excluded from the accompanying results of operations for all periods presented, unless otherwise noted. See Note 3 – discontinued operations in the accompanying notes to consolidated financial statements. Further, as a result of any acquisitions of other businesses, and any additional pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to the transactions that are not incident to our operations.

 

Comparison of the Three Months Ended March 31, 2024 and 2023

 

Operating Expenses

 

Our total operating expenses for the three months ended March 31, 2024, were $135,476. For the comparable period in 2023, the operating expenses were $1,344,426. The decrease is the result of the winding down of the Company’s clinic operations with The Good Clinic, LLC subsidiary.

 

Other Income and Expenses

 

Interest expense was $40,624 for the three months ended March 31, 2024, compared to 1,376,066 for the three months ended March 31, 2023. The decrease was a result of reduced debt balances in the current period.

 

Interest expense – related parties was $10,581 for the three months ended March 31, 2024, compared to $44,777 in the prior period. The decrease was a result of reduced debt balances in the current period.

 

For the three months ended March 31, 2024, we had a net loss available to common shareholders from discontinued operations of $0, compared to a net loss available to common shareholders from discontinued operations of $2,325,044.

 

27

 

Liquidity and Capital Resources

 

To date, we have not generated sufficient revenue from operations to support our operations. We have financed our operations through sale of equity securities and short-term borrowings. As of May [ ], 2024, we had cash of approximately $12,000 compared to cash of approximately $41,000 as of March 31, 2024.

 

Net cash used in operating activities was $154,267 for the three months ended March 31, 2024. This is the result of the winding down of the Company’s clinic operations. Cash used in operations for the three months ended March 31, 2023, was $35,324.

 

The Company had no investing activities for the three months ended March 31, 2024 and 2023.

 

Net cash provided by financing activities for the three months ended March 31, 2024, was 192,214, compared to $0 for the three months ended March 31, 2023. Cash provided by financing activities was the result of cash proceeds from notes payable, offset by the repayment of principal on the SBA loan in the amount of $7,786

 

At March 31, 2024, we had the following current liabilities which are payable in cash: Accounts payable and accrued liabilities of $7.4 million; notes payable of $1.3 million; notes payable to related parties of $.2 million; SBA Loan Payable of $0.4 million; legal settlements of $2.5 million; accrued interest payable of $0.4 million; accrued interest payable to related parties of $0.01 million; and other current liabilities of $0.1 million. We also have the following liabilities which are payable in stock: derivative liabilities of $0.2 million, preferred stock dividends of $2.0 million, and preferred stock dividends payable to related parties of $0.2 million.

 

We have undertaken the following action plan to improve our liquidity: (i) We have raised approximately $194,000 from the sale of office equipment, supplies, and other assets; (ii) several institutional investors have invested in our Series F Preferred Stock; (iii) we have restructured our SBA Loan; (iv) we are negotiating with vendors to convert our accounts payable into common stock or Series F Preferred stock, (iv) We are negotiating with lenders to convert our notes payable into restricted common or preferred stock, or revise the terms of the notes; (v) We are negotiating with landlords to resolve the amounts due under the leases by offering to convert these amounts to equity or promissory notes. See below for details regarding the progress we have made in the implementation of this plan.

 

Initial funds raised via the above efforts will be used primarily to complete the Company’s SEC filings and to fund legal costs related to the winding down of our previous operations.

 

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

 

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,786

 

 

 

28

 

Critical Accounting Estimates

 

Management uses various estimates and assumptions in preparing our financial statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accounting estimates that are the most important to the presentation of our results of operations and financial condition, and which require the greatest use of judgment by management, are designated as our critical accounting estimates. We have the following critical accounting estimates:

 

 

Estimates and assumptions used in the valuation of derivative liabilities: Management utilizes a lattice model to estimate the fair value of derivative liabilities. The model includes subjective assumptions that can materially affect the fair value estimates.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

(a) Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluation, the Company’s management has identified what it believes are material weaknesses in the Company’s disclosure controls and procedures and concluded that we did not have effective disclosure controls and procedures.

 

The deficiencies in our disclosure controls and procedures included (i) lack of segregation of duties and (ii) lack of sufficient resources to ensure that information required to be disclosed by the Company in the reports that the Company files or submits to the SEC are recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms.

 

The Company intends to take corrective action to ensure that information required to be disclosed by the Company pursuant to the reports that the Company files or submits to the SEC is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

(b) Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our first quarter ended March 31, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

29

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. Mitesco (Company) was not named in the suit. We have settled this matter as of January 11, 2024 for total consideration consisting of a cash payment of $3,000.

 

On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

 

Nordhaus Clinic

 

On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received by the landlord and the Company believes no additional amounts are owed.

 

Egan Clinic a.k.a. Vikings

 

On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023 and the Company has released the property back to the leaseholder.

 

St. Paul Clinic a.k.a. The Grove

 

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023 in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

 

St. Louis Park Clinic a.k.a. Excelsior & Grand

 

On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,351 on April 2, 2024 and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024.

 

Eden Prairie Clinic a.k.a. TP Elevate

 

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations the amounts owed and is in the process of settling the remaining amounts owed.

 

30

 

Maple Grove Clinic a.k.a. Arbor Lakes

 

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company has released the property back to the leaseholder.

 

Radiant Clinic a.k.a. LMC Welton

 

On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder.

 

Quincy Clinic a.k.a. 1776 Curtis

 

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder.

 

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

 

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,768

 

 

 

Administrative offices

 

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not entered into a settlement agreement on this site as of the date of this filing but expect to shortly.

 

31

 

ITEM 1A. RISK FACTORS

 

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on July 14, 2023. There have been no material changes to the risk factors described in that report.

 

ITEM 2. SALE OF UNREGISTERED SECURITIES

 

Common Stock

 

During the three months ended March 31, 2024, the Company issued 66,070 shares of common stock for dividends payable on its Series X Preferred Stock.

 

ITEM 3. DEFAULTS ON SENIOR SECURED SECURITIES

 

Not Applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

ITEM 5. OTHER INFORMATION

 

Not Applicable.

 

ITEM 6. EXHIBITS

 

The following exhibits are included with this Quarterly Report on Form 10Q

 

 

 

 

 

Form

Type

 

Exhibit

Number

 

Date

Filed

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Certificate of Incorporation of Trunity Holdings, Inc., dated January 18, 2012.

 

8-K

 

10.1

 

1/31/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Bylaws of Trunity Holdings, Inc., dated January 18, 2012.

 

8-K

 

10.2

 

1/31/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.3

 

Certificate of Ownership Merging between Trunity Holdings, Inc. and Brain Tree International, Inc. dated January 24, 2012.

 

10-K

 

3.3

 

4/16/2013

 

 

 

 

 

 

 

 

 

 

 

 

 

3.4

 

Certificate of Amendment to the Certificate of Incorporation of Trunity Holdings, Inc., dated December 24, 2015.

 

8-K

 

3.1(i)

 

1/06/2016

 

 

 

 

 

 

 

 

 

 

 

 

 

3.5

 

Certificate of Designations of Series X Preferred Stock of True Nature Holding, Inc.

 

8-K

 

3.6

 

1/06/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.6

 

Form of Amended and Restated Certificate of Designations of Series A Preferred Stock of True Nature Holding, Inc.

 

8-K

 

3.07

 

3/13/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.7

 

Certificate of Amendment of the Certificate of Incorporation of True Nature Holding, Inc. dated April 21, 2020.

 

10-Q

 

3.7

 

8/14/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.8

 

Certificate of Amendment of Certificate of Incorporation, dated as of November 5, 2020, correcting December 24, 2015, Certificate of Amendment.

 

10-Q

 

3.8

 

11/13/2020

 

 

 

32

 

 

 

 

 

Form

Type

 

Exhibit

Number

 

Date

Filed

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

 

3.9

 

Bylaws of Mitesco, Inc., as amended, dated November 10, 2020

 

10-Q

 

3.9

 

11/13/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.10

 

Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.

 

8-K

 

3.1

 

03/26/2021

 

 

 

 

 

 

 

 

 

 

 

 

 

3.11

 

Certificate of Correction to the Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.

 

8-K

 

3.2

 

03/26/2021

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification by the Principal Executive Officer of the Registrant pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification by the Principal Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.INS **

 

XBRL INSTANCE DOCUMENT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH **

 

XBRL TAXONOMY EXTENSION SCHEMA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL **

 

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF **

 

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB **

 

XBRL TAXONOMY EXTENSION LABEL LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE **

 

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

#

 

 

Management contract or compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this report.

 

 

 

 

 

 

 

 

 

33

 

SIGNATURE

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q for the period ended March 31, 2024, to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

MITESCO, INC.

 

 

 

 

Dated: May 15, 2024

By:

/s/ Mack Leath

 

 

 

Mack Leath

Chief Executive Officer, Chief Financial Officer and Principal Financial Officer

 

 

 

 

34
false --12-31 Q1 0000802257 0000802257 2024-01-01 2024-03-31 0000802257 2024-05-12 0000802257 2024-03-31 0000802257 2023-12-31 0000802257 us-gaap:NonrelatedPartyMember 2024-03-31 0000802257 us-gaap:NonrelatedPartyMember 2023-12-31 0000802257 us-gaap:RelatedPartyMember 2024-03-31 0000802257 us-gaap:RelatedPartyMember 2023-12-31 0000802257 us-gaap:SeriesAPreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesAPreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesCPreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesCPreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesDPreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesDPreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesFPreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesFPreferredStockMember 2023-12-31 0000802257 miti:SeriesXPreferredStockMember 2024-03-31 0000802257 miti:SeriesXPreferredStockMember 2023-12-31 0000802257 2023-01-01 2023-03-31 0000802257 us-gaap:NonrelatedPartyMember 2024-01-01 2024-03-31 0000802257 us-gaap:NonrelatedPartyMember 2023-01-01 2023-03-31 0000802257 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0000802257 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 us-gaap:CommonStockMember 2023-12-31 0000802257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000802257 us-gaap:RetainedEarningsMember 2023-12-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2024-01-01 2024-03-31 0000802257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000802257 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 us-gaap:CommonStockMember 2024-03-31 0000802257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000802257 us-gaap:RetainedEarningsMember 2024-03-31 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 us-gaap:CommonStockMember 2022-12-31 0000802257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000802257 miti:StockSubscribedMember 2022-12-31 0000802257 us-gaap:RetainedEarningsMember 2022-12-31 0000802257 2022-12-31 0000802257 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000802257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000802257 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 us-gaap:CommonStockMember 2023-03-31 0000802257 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000802257 miti:StockSubscribedMember 2023-03-31 0000802257 us-gaap:RetainedEarningsMember 2023-03-31 0000802257 2023-03-31 0000802257 miti:StockSubscribedMember 2024-01-01 2024-03-31 0000802257 miti:StockSubscribedMember 2023-01-01 2023-03-31 0000802257 2023-12-08 2023-12-08 0000802257 miti:PPPLoanMember 2020-05-04 0000802257 2023-07-12 2023-07-12 0000802257 2023-07-12 0000802257 miti:PPPLoanMember 2023-01-01 2023-12-31 0000802257 miti:PPPLoanMember 2023-12-31 0000802257 miti:PPPLoanMember 2024-01-01 2024-03-31 0000802257 miti:PPPLoanMember miti:AccruedInterestMember 2024-01-01 2024-03-31 0000802257 miti:KishonNoteMember 2022-05-10 2022-05-10 0000802257 miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember miti:OriginalIssueDiscountMember 2022-05-10 0000802257 srt:MinimumMember miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-05-10 0000802257 miti:KishonNoteMember miti:DefaultPenaltyMember 2023-12-31 0000802257 miti:KishonNoteMember 2023-12-31 0000802257 miti:KishonNoteMember 2024-03-31 0000802257 miti:FinneganNote1Member 2022-05-23 0000802257 miti:FinneganNote1Member 2022-05-23 2022-05-23 0000802257 miti:FinneganNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-23 0000802257 miti:WarrantsAt2500Member miti:FinneganNote1Member 2022-05-23 2022-05-23 0000802257 miti:WarrantsAt2500Member miti:FinneganNote1Member 2022-05-23 0000802257 miti:FinneganNote1Member 2023-12-31 0000802257 miti:FinneganNote1Member 2024-03-31 0000802257 miti:FinneganNote2Member 2022-05-26 0000802257 miti:FinneganNote2Member 2022-05-26 2022-05-26 0000802257 miti:FinneganNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:FinneganNote2Member 2022-05-26 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:FinneganNote2Member 2022-05-26 0000802257 miti:FinneganNote2Member 2023-12-31 0000802257 miti:FinneganNote2Member 2024-03-31 0000802257 miti:SchrierNoteMember 2022-07-07 0000802257 miti:SchrierNoteMember 2022-07-07 2022-07-07 0000802257 miti:SchrierNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-07 0000802257 miti:WarrantsAt2500Member miti:SchrierNoteMember 2022-07-07 0000802257 miti:SchrierNoteMember 2023-12-31 0000802257 miti:SchrierNoteMember 2024-03-31 0000802257 miti:NommsenNoteMember 2022-07-26 0000802257 miti:NommsenNoteMember 2022-07-26 2022-07-26 0000802257 miti:NommsenNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-26 0000802257 miti:WarrantsAt2500Member miti:NommsenNoteMember 2022-07-26 2022-07-26 0000802257 miti:WarrantsAt2500Member miti:NommsenNoteMember 2022-07-26 0000802257 miti:NommsenNoteMember 2023-12-31 0000802257 miti:NommsenNoteMember 2024-03-31 0000802257 miti:CaplanNoteMember 2022-07-27 0000802257 miti:CaplanNoteMember 2022-07-27 2022-07-27 0000802257 miti:CaplanNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-27 0000802257 miti:WarrantsAt2500Member miti:CaplanNoteMember 2022-07-27 2022-07-27 0000802257 miti:WarrantsAt2500Member miti:CaplanNoteMember 2022-07-27 0000802257 miti:CaplanNoteMember 2023-12-31 0000802257 miti:CaplanNoteMember 2024-03-31 0000802257 miti:FinneganNote3Member 2022-08-04 0000802257 miti:FinneganNote3Member 2022-08-04 2022-08-04 0000802257 miti:FinneganNote3Member us-gaap:MeasurementInputDefaultRateMember 2022-08-04 0000802257 miti:WarrantsAt2500Member miti:FinneganNote3Member 2022-08-04 2022-08-04 0000802257 miti:WarrantsAt2500Member miti:FinneganNote3Member 2022-08-04 0000802257 miti:FinneganNote3Member 2023-12-31 0000802257 miti:FinneganNote3Member 2024-03-31 0000802257 miti:LightmasNoteMember 2022-09-02 0000802257 miti:LightmasNoteMember 2022-09-02 2022-09-02 0000802257 miti:LightmasNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:LightmasNoteMember 2023-12-31 0000802257 miti:LightmasNoteMember 2024-03-31 0000802257 miti:LewisNoteMember 2022-09-02 0000802257 miti:LewisNoteMember 2022-09-02 2022-09-02 0000802257 miti:LewisNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:LewisNoteMember 2023-12-31 0000802257 miti:LewisNoteMember 2024-03-31 0000802257 miti:GoffNoteMember 2022-09-02 0000802257 miti:GoffNoteMember 2022-09-02 2022-09-02 0000802257 miti:GoffNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:GoffNoteMember 2023-12-31 0000802257 miti:GoffNoteMember 2024-03-31 0000802257 miti:HaganNoteMember 2022-09-02 0000802257 miti:HaganNoteMember 2022-09-02 2022-09-02 0000802257 miti:HaganNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:HaganNoteMember 2023-12-31 0000802257 miti:HaganNoteMember 2024-03-31 0000802257 miti:CavalryNote1Member 2024-01-23 0000802257 miti:CavalryNote1Member us-gaap:MeasurementInputDefaultRateMember 2024-01-23 0000802257 miti:CavalryNote1Member 2024-03-31 0000802257 miti:CavalryNote2Member 2024-02-28 0000802257 miti:CavalryNote2Member us-gaap:MeasurementInputDefaultRateMember 2024-02-28 0000802257 miti:CavalryNote2Member 2024-03-31 0000802257 miti:MercerNote1Member 2024-01-23 0000802257 miti:MercerNote1Member 2024-01-23 2024-01-23 0000802257 miti:MercerNote1Member us-gaap:MeasurementInputDefaultRateMember 2024-01-23 0000802257 miti:MercerNote1Member 2024-03-31 0000802257 miti:MercerNote2Member 2024-02-28 0000802257 miti:MercerNote2Member 2024-02-28 2024-02-28 0000802257 miti:MercerNote2Member 2024-03-31 0000802257 miti:MercerNote2Member 2024-01-01 2024-03-31 0000802257 miti:AJBCapitalNoteMember 2024-02-28 0000802257 miti:MercerNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-09-15 0000802257 miti:AJBCapitalNoteMember 2024-03-31 0000802257 us-gaap:NotesPayableOtherPayablesMember 2024-03-31 0000802257 us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0000802257 miti:CavalryNote1Member 2023-12-31 0000802257 miti:CavalryNote2Member 2023-12-31 0000802257 miti:MercerNoteMember 2024-03-31 0000802257 miti:MercerNoteMember 2023-12-31 0000802257 miti:CavalryNote3Member 2024-03-31 0000802257 miti:CavalryNote3Member 2023-12-31 0000802257 miti:AJBCapitalNoteMember 2023-12-31 0000802257 miti:MDiamondNoteMember 2022-05-26 0000802257 miti:MDiamondNoteMember 2022-05-26 2022-05-26 0000802257 miti:MDiamondNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:MDiamondNoteMember 2022-05-26 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:MDiamondNoteMember 2022-05-26 0000802257 miti:MDiamondNoteMember 2023-12-31 0000802257 miti:MDiamondNoteMember 2024-03-31 0000802257 miti:DobbertinNote1Member 2022-05-26 0000802257 miti:DobbertinNote1Member 2022-05-26 2022-05-26 0000802257 miti:DobbertinNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:DobbertinNote1Member 2022-05-26 0000802257 miti:DobbertinNote1Member 2023-12-31 0000802257 miti:DobbertinNote1Member 2024-03-31 0000802257 miti:LindstromNote1Member 2022-05-26 0000802257 miti:LindstromNote1Member 2022-05-26 2022-05-26 0000802257 miti:LindstromNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:LindstromNote1Member 2022-05-26 0000802257 miti:LindstromNote1Member 2023-12-31 0000802257 miti:LindstromNote1Member 2024-03-31 0000802257 miti:MitchellNoteMember 2022-06-09 0000802257 miti:MitchellNoteMember 2022-06-09 2022-06-09 0000802257 miti:MitchellNoteMember 2021-12-30 2021-12-30 0000802257 miti:MitchellNoteMember 2021-12-30 0000802257 miti:MitchellNoteMember us-gaap:MeasurementInputDefaultRateMember 2021-12-30 0000802257 miti:MitchellNoteMember miti:WarrantsAt2500Member 2021-12-30 2021-12-30 0000802257 miti:MitchellNoteMember 2023-12-31 0000802257 miti:MitchellNoteMember 2024-03-31 0000802257 miti:LeathNoteMember 2022-09-15 0000802257 miti:LeathNoteMember 2022-09-15 2022-09-15 0000802257 miti:LeathNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-15 0000802257 miti:LeathNoteMember 2023-12-31 0000802257 miti:LeathNoteMember 2024-03-31 0000802257 miti:November292022NotesMember 2022-11-29 2022-11-29 0000802257 miti:November292022NotesMember us-gaap:MeasurementInputDefaultRateMember 2022-11-29 0000802257 miti:November292022NotesMember 2022-01-01 2022-12-31 0000802257 miti:November292022NotesMember 2022-12-31 0000802257 miti:November292022NotesMember 2023-01-01 2023-12-31 0000802257 miti:InvestmentIncentiveMember miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 us-gaap:ConvertibleNotesPayableMember miti:November292022NotesMember us-gaap:SeriesFPreferredStockMember 2023-09-29 2023-09-29 0000802257 miti:AccruedInterestMember miti:November292022NotesMember us-gaap:SeriesFPreferredStockMember 2023-09-29 2023-09-29 0000802257 miti:November292022NotesMember us-gaap:SeriesFPreferredStockMember 2023-09-29 2023-09-29 0000802257 miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 us-gaap:ConvertibleNotesPayableMember miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 miti:AccruedInterestMember miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 miti:November292022NotesMember 2023-09-29 0000802257 us-gaap:ConvertibleNotesPayableMember miti:HoweNoteMember 2023-12-08 2023-12-08 0000802257 miti:AccruedInterestMember miti:HoweNoteMember 2023-12-08 2023-12-08 0000802257 miti:November292022NotesMember 2023-12-31 0000802257 miti:November292022NotesMember 2024-03-31 0000802257 miti:MDiamondNoteMember us-gaap:RelatedPartyMember 2024-03-31 0000802257 miti:MDiamondNoteMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:DobbertinNote1Member us-gaap:RelatedPartyMember 2024-03-31 0000802257 miti:DobbertinNote1Member us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:LindstromNote1Member us-gaap:RelatedPartyMember 2024-03-31 0000802257 miti:LindstromNote1Member us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:MitchellNoteMember us-gaap:RelatedPartyMember 2024-03-31 0000802257 miti:MitchellNoteMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:LeathNoteMember us-gaap:RelatedPartyMember 2024-03-31 0000802257 miti:LeathNoteMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:November292022NotesMember us-gaap:RelatedPartyMember 2024-03-31 0000802257 miti:November292022NotesMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 srt:MinimumMember 2023-01-01 2023-12-31 0000802257 srt:MaximumMember 2023-01-01 2023-12-31 0000802257 srt:MinimumMember 2023-12-31 0000802257 srt:MaximumMember 2023-12-31 0000802257 us-gaap:SeriesEPreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0000802257 us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-03-31 0000802257 us-gaap:SeriesDPreferredStockMember 2024-01-01 2024-03-31 0000802257 us-gaap:SeriesEPreferredStockMember 2022-11-07 2022-11-07 0000802257 us-gaap:SeriesEPreferredStockMember 2022-11-07 0000802257 us-gaap:SeriesFPreferredStockMember 2023-03-23 0000802257 us-gaap:SeriesFPreferredStockMember 2024-01-01 2024-03-31 0000802257 miti:SeriesXPreferredStockMember 2024-01-01 2024-03-31 0000802257 miti:SeriesXPreferredStockMember 2023-07-01 0000802257 miti:SeriesXPreferredStockMember 2023-07-01 2023-07-01 0000802257 us-gaap:CommonStockMember 2023-07-01 0000802257 miti:SeriesXPreferredStockMember 2024-02-09 2024-02-09 0000802257 miti:SeriesXPreferredStockMember 2024-03-20 2024-03-20 0000802257 miti:TwoServiceProvidersMember us-gaap:SeriesFPreferredStockMember 2024-03-20 0000802257 us-gaap:EmployeeStockOptionMember 2024-03-31 0000802257 srt:MinimumMember 2024-03-31 0000802257 srt:MaximumMember 2024-03-31 0000802257 us-gaap:FairValueInputsLevel1Member 2024-03-31 0000802257 us-gaap:FairValueInputsLevel2Member 2024-03-31 0000802257 us-gaap:FairValueInputsLevel3Member 2024-03-31 0000802257 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000802257 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000802257 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000802257 2024-01-11 2024-01-11 0000802257 us-gaap:RestrictedStockMember us-gaap:SettledLitigationMember 2022-10-25 2022-10-25 0000802257 miti:CEOOfTheGoodClinicMember us-gaap:RestrictedStockMember us-gaap:SettledLitigationMember 2022-10-25 2022-10-25 0000802257 2022-10-25 2022-10-25 0000802257 2020-11-01 0000802257 2021-10-14 0000802257 us-gaap:JudicialRulingMember 2023-12-15 2023-12-15 0000802257 2023-12-15 0000802257 us-gaap:JudicialRulingMember 2023-12-21 2023-12-21 0000802257 2021-05-04 0000802257 us-gaap:JudicialRulingMember 2024-04-02 2024-04-02 0000802257 2021-06-08 0000802257 2021-10-08 0000802257 us-gaap:JudicialRulingMember 2022-10-22 2022-10-22 0000802257 2021-09-21 0000802257 us-gaap:SettledLitigationMember 2024-04-10 2024-04-10 0000802257 2021-09-28 0000802257 us-gaap:JudicialRulingMember 2023-11-14 2023-11-14 0000802257 2023-11-14 0000802257 miti:NordhausMinneapolisMNMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:NordhausMinneapolisMNMember 2024-03-31 0000802257 miti:ProminadeWayzettaMNMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:ProminadeWayzettaMNMember 2024-03-31 0000802257 miti:EaganClinicEaganMNMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:EaganClinicEaganMNMember 2024-03-31 0000802257 miti:ExcelsiorGrandStLouisParkMNMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:ExcelsiorGrandStLouisParkMNMember 2024-03-31 0000802257 miti:TheGroveStPaulMNMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:TheGroveStPaulMNMember 2024-03-31 0000802257 miti:ElevateEdenPrarieMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:ElevateEdenPrarieMember 2024-03-31 0000802257 miti:ArborLakesMapleGraveMNMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:ArborLakesMapleGraveMNMember 2024-03-31 0000802257 miti:LMCWeltonDenverCOMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:LMCWeltonDenverCOMember 2024-03-31 0000802257 miti:Curtis1776DenverCOMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember miti:Curtis1776DenverCOMember 2024-03-31 0000802257 us-gaap:SettledLitigationMember 2024-03-31 0000802257 us-gaap:RestrictedStockMember 2024-03-19 2025-03-19 0000802257 us-gaap:RestrictedStockMember 2024-03-19 0000802257 us-gaap:OtherAffiliatesMember 2024-03-19 2024-03-19 0000802257 2024-03-19 2024-03-19 0000802257 us-gaap:RestrictedStockMember 2024-04-26 0000802257 us-gaap:OtherAffiliatesMember 2024-04-26 2024-04-26 0000802257 2024-04-26 2024-04-26 0000802257 us-gaap:OtherAffiliatesMember 2024-05-10 2024-05-10 0000802257 2024-05-10 2024-05-10 0000802257 us-gaap:RestrictedStockMember 2024-05-10 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure